Phaseline

Companies › Unravel Biosciences

Unravel Biosciences: clinical trials, targets and expected readouts

1 active drug program in 24 registered trials: 18 Phase 1, 6 Phase 2; Hematology, Immunology, Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vorinostat
Histone deacetylase 1 inhibitor; Histone deacetylase 3 inhibitor; Histone deacetylase 6 inhibitor
HDAC (class I/II)Phase 1Rett Syndrome; Pitt Hopkins Syndrome; Castration-Resistant Prostate Carcinoma; Metastatic Uveal Melanoma …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03842696VorinostatPhase 1Hematologic DiseasesOncologyJul 2025
NCT01087554VorinostatPhase 1Advanced CancerOncologyAug 2026
NCT03742245VorinostatPhase 1Breast Cancer MetastaticOncologyDec 2026
NCT06145633VorinostatPhase 2Castration-Resistant Prostate CarcinomaOncologyDec 2026
NCT07150013VorinostatPhase 1Rett SyndromePsychiatryDec 2026
NCT07150026VorinostatPhase 1Pitt Hopkins SyndromeOtherDec 2026
NCT01587352VorinostatPhase 2Metastatic Uveal MelanomaOncologyDec 2026
NCT00392353VorinostatPhase 1Acute Erythroid LeukemiaHematologyDec 2026
NCT04308330VorinostatPhase 1Ewing SarcomaOncologyDec 2026
NCT05317403VorinostatPhase 1Acute Myeloid Leukemia, in RelapseOncologyJan 2027
NCT00616967VorinostatPhase 2Breast CancerOncologyFeb 2027
NCT00972478VorinostatPhase 1Ann Arbor Stage II Non-Hodgkin LymphomaOncologyMar 2027
NCT01522976VorinostatPhase 2Chronic Myelomonocytic LeukemiaHematologyMar 2027
NCT00336063VorinostatPhase 1Adult Nasal Type Extranodal NK/T-Cell LymphomaOncologyMar 2027
NCT01281176VorinostatPhase 1Adult Solid NeoplasmOncologyApr 2027
NCT00268385VorinostatPhase 1Adult Anaplastic AstrocytomaOncologyApr 2027
NCT03150329VorinostatPhase 1Grade 3b Follicular LymphomaOncologyJun 2027
NCT01297764VorinostatPhase 1Multiple MyelomaOncologyJun 2027
NCT02638090VorinostatPhase 1Lung CancerOncologyJun 2027
NCT03843528VorinostatPhase 1Acute Myeloid LeukemiaOncologyJul 2027
NCT06995521VorinostatPhase 2GVHDImmunologySep 2028
NCT02559778VorinostatPhase 2NeuroblastomaOncologySep 2030
NCT02553460VorinostatPhase 1Acute Lymphoblastic LeukemiaOncologyOct 2031
NCT03167437VorinostatPhase 1Crohn's DiseaseImmunologyJun 2035

Targets

HDAC (class I/II) (1)

Companies with the same targets

Xynomic Pharmaceuticals Jubilant Therapeutics Great Novel Therapeutics Biotech & Medicals Italfarmaco Daiichi Sankyo Chengdu Zenitar Biomedical Technology Acrotech Biopharma Novelwise Pharmaceutical Chipscreen Biosciences Novartis

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.